Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02350777 · ClinicalTrials.gov registry record · Phase 2
T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02350777: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02350777 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02350777, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy. The investigators want to see if this can improve bone marrow function. This would also improve the patients white blood counts, red blood counts and platelets. This may make the patients chances of improving and surviving better. The investigators will also be looking at the short term side effects and risks of the TCD boost.
Interventions
- PROCEDURE Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion
- DEVICE CliniMACS Cell Selection System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2017-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02350777
The ClinicalTrials.gov registry entry for NCT02350777 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion is the first listed.
NCT02350777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02350777 about?
NCT02350777 is a clinical study titled "T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation". The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy. The investigators want to see if this can improve bone marrow function. This would also improve the patients white b...
What is the current status of trial NCT02350777?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-01-21. Estimated completion is 2017-10-25.
What interventions are being tested in trial NCT02350777?
The interventions under investigation include: Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion (PROCEDURE), CliniMACS Cell Selection System (DEVICE).
Who is sponsoring clinical trial NCT02350777?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.